The acquisition will extend Lilly's research efforts through the creation of a gene therapy program anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets. Currently in development are PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease, as well as PR006 for patients with frontotemporal dementia with GRN mutations.

In Prevail's preclinical pipeline are PR004 for patients with specific synucleinopathies, as well as potential gene therapies for Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders.

To receive the full $1.04 billion, regulatory approval for one of Prevail's products must be received by December 31, 2024.

Regulatory Roundup: Designations come through before year's end
This week's Regulatory Roundup covers activities from November 30 to December 4 and is filled with breakthrough, orphan, and rare disease designations...

Lilly to provide U.S. with 650K more COVID-19 antibody doses
The U.S. government has purchased an additional 650,000 doses of Eli Lilly's neutralizing antibody, bamlanivimab, for $812.5 million.

FDA issues EUA for Lilly's JAK inhibitor plus remdesivir for COVID-19
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the drug baricitinib, a janus kinase (JAK) inhibitor,...

Lilly, Precision BioSciences collaborate on genome editing
Eli Lilly and Precision BioSciences have entered a research collaboration and exclusive licensing agreement to utilize Precision's proprietary Arcus genome...

Prevail Therapeutics granted gene therapy patent
The U.S. Patent and Trademark Office has issued a composition of matter patent (No. 10,837,028) to Prevail Therapeutics for its adeno-associated viral...